Renovacor recently announced the successful completion of an $11 million Series A financing co-led by Novartis Venture Fund, Broadview Ventures, and BioAdvance, and joined by New Leaf Venture Partners and Innogest Capital. There are currently no precision medicine options for cardiovascular patients with specific genetic mutations — a deficiency that Renovacor hopes to address. I talked to Dr. Maggie Cook, president and CEO of Renovacor about how the company plans to address this deficiency and to determine what patients with DCM can expect if the gene therapy development is successful.
By Christina Bennett,GE Healthcare Life Sciences
Overcoming the challenges of manufacturing and administering a complex product to any patient is critical for delivering cell therapies. Two industry experts detail strategies to meet supply chain challenges.
White Paper |
By Tom Piombino and Sue Behrens,Integrated Project Services (IPS)
The movement of viral vectors, cell therapies, and other antibody-based next-generation drug products toward commercialization is driving the need for new and different technologies and facilities. Engineering and design firms with the right skill sets can help you maintain the right balance in your facility design to maintain flexibility, which is essential to meet diverse processing needs for biopharmaceutical manufacturing.